… its incorporation into subsequent targeted therapy trials in lung cancer with other actionable
… profiling of lung cancers has also revealed the genetic heterogeneity in lung cancers, where …

… Targeted therapy has emerged as an … cell lung cancer (NSCLC). Herein, we review and
analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer…

… cancer: gefitinib in 2002, erlotinib in 2003, bevacizumab in … the targeted therapies in lung
cancer: the molecular biomarkers that help identify patients likely to benefit from these targeted …

… management of non-small cell lung cancer (NSCLC). NSCLC … a known driver mutation,
targeted therapy is pushing the … well as the development of targeted agents available to treat …

… state-of-the-art research for targeted therapy in NSCLC. … -cell lung cancer (NSCLC) accounts
for 85% of all lung cancers. … Targeted therapy has been successful in other malignancies, …

… targeting EGFR family members, novel EML4-ALK inhibitors and MEK inhibitors are currently
in clinical development. Availability of targeted … advances in use of targeted therapy, with a …

… cancer growth. In this comprehensive review, we look back at developments in targeted therapy
for advanced non-small-cell lung cancer, … cases less so, to target EGFR, VEGF and ALK. …

… Targeted therapy of lung cancer Lung cancer is considered the number one killer among
all cancers. In the USA alone, 226 160 new cases (14% of …

… Lung cancer is the leading cause of cancer deaths world-wide. Recent advances in cancer
… targets in neoplastic cells and the development of novel targeted therapies. At this time, two …

… , targeted therapy continues to provide durable responses. Advances in molecular and
immunohistochemical techniques have made it possible to usher lung cancer … targeted therapy, …